Journal
FRONTIERS IN AGING NEUROSCIENCE
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fnagi.2021.646901
Keywords
Alzheimer' s disease; genetics; biomarker; molecular pathways; gene ontology
Categories
Funding
- Slovenian Research Agency (ARRS) [P1-0170]
- European Union's Horizon 2020 research and innovation programme [951851]
Ask authors/readers for more resources
Alzheimer's disease is a neurodegenerative disease that affects a significant portion of the elderly population, leading to a major burden on the healthcare system due to rapid aging of the population. Despite the lack of effective drug treatment, genetic studies have identified numerous genes associated with increased risk of AD. This information may help in identifying novel molecular targets for the development of tailored and personalized treatments for Alzheimer's disease.
Alzheimer's disease (AD) is a complex neurodegenerative disease, affecting a significant part of the population. The majority of AD cases occur in the elderly with a typical age of onset of the disease above 65 years. AD presents a major burden for the healthcare system and since population is rapidly aging, the burden of the disease will increase in the future. However, no effective drug treatment for a full-blown disease has been developed to date. The genetic background of AD is extensively studied; numerous genome-wide association studies (GWAS) identified significant genes associated with increased risk of AD development. This review summarizes more than 100 risk loci. Many of them may serve as biomarkers of AD progression, even in the preclinical stage of the disease. Furthermore, we used GWAS data to identify key pathways of AD pathogenesis: cellular processes, metabolic processes, biological regulation, localization, transport, regulation of cellular processes, and neurological system processes. Gene clustering into molecular pathways can provide background for identification of novel molecular targets and may support the development of tailored and personalized treatment of AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available